ERBB2 and breast carcinoma: In the neoadjuvant trastuzumab and lapatinib treatment optimization (NeoALTTO) trial, it appears that women suffering from HER2-positive breast carcinoma experienced a significant improvement in achieving a pCR when treated by adding lapatinib to trastuzumab as compared to using only one anti-HER2 agent for the treatment [49].